| Product Code: ETC051370 | Publication Date: Aug 2023 | Updated Date: Jun 2026 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The Vietnam Gastrointestinal Drugs Market was estimated at USD 157 Million in 2025 and is projected to reach USD 220 Million by 2032, growing at a CAGR of 4.9% from 2026 to 2032. This growth trajectory is largely driven by the increasing prevalence of gastrointestinal disorders, which are on the rise due to changing dietary patterns and lifestyles. Coupled with enhanced healthcare access and awareness, the demand for effective gastrointestinal medications is expected to see significant upticks as the population seeks better management options.
This graph highlights how the Vietnam Gastrointestinal Drugs Market has steadily grown over the years, supported by major growth factors.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate | Major Drivers |
| 2021 | 3.1% | Increasing smart city development projects |
| 2022 | 2.7% | Expansion of commercial construction activities |
| 2023 | 8.2% | Increasing adoption of advanced technologies |
| 2024 | 5.2% | Rising electricity demand across industries |
| 2025 | 6.4% | Increasing smart city development projects |
| 2026 | 8.0% | Increasing industrial automation investments |
| 2027 | 7.3% | Expansion of commercial construction activities |
| 2028 | 6.1% | Increasing smart city development projects |
| 2029 | 6.0% | Government infrastructure modernization initiatives |
| 2030 | 5.5% | Increasing industrial automation investments |
| 2031 | 5.3% | Increasing industrial infrastructure investments |
| 2032 | 5.9% | Increasing adoption of advanced technologies |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch’s advanced forecasting approach, validated with industry datasets as of June 2026.
The landscape of gastrointestinal health in Vietnam is changing rapidly, propelled by the nation’s evolving healthcare infrastructure and a growing recognition of the importance of digestive health. Notably, conditions such as gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS) are becoming increasingly common, underscoring the urgent need for effective pharmaceutical interventions.
Moreover, the COVID-19 pandemic has placed unprecedented strain on healthcare services, momentarily hindering access to gastrointestinal treatments. However, as the healthcare system stabilizes and adapts, the renewed focus on gastrointestinal health is expected to bolster demand for effective drug therapies, enabling better patient outcomes.
Despite the growth potential, the Vietnam gastrointestinal drugs market faces notable restraints that could hinder its progress. The high costs associated with certain medications can limit accessibility for a significant portion of the population. Furthermore, the prevalent use of over-the-counter treatments means that patients may not always seek out necessary prescription therapies, potentially stunting market expansion. There is also the ongoing challenge of counterfeit drugs in the market, which not only compromises patient safety but also undermines overall trust in the pharmaceutical industry, making effective regulation imperative.
The Vietnam gastrointestinal drugs market is currently witnessing trends that reflect broader changes in healthcare and consumer behavior. An increasing awareness of digestive health is prompting patients to seek specialized treatments, while the integration of telemedicine and online consultations is making access to gastroenterologists easier. Additionally, the pharmaceutical industry is focusing on developing innovative formulations and delivery systems that cater to the specific needs of the Vietnamese population, which is crucial for improving treatment efficacy.
Investment opportunities in the Vietnam gastrointestinal drugs market are robust, especially in areas such as research and development of new drug formulations targeting specific local conditions. As the healthcare system continues to improve, there’s also room for partnerships with healthcare providers to enhance patient education on gastrointestinal health. Furthermore, as awareness grows, businesses can capitalize on developing over-the-counter solutions that complement prescription therapies, paving the way for broader market growth.
The Vietnamese government has implemented various initiatives aimed at improving healthcare services, which indirectly benefit the gastrointestinal drugs market. Increased public spending on healthcare infrastructure and programs to enhance disease prevention are in place, supporting the delivery of better medical services. Moreover, regulatory efforts to ensure drug safety and efficacy are being bolstered, providing a more secure environment for both patients and pharmaceutical companies.
Looking towards 2026-2032, the Vietnam gastrointestinal drugs market is poised for substantial growth. The combination of an aging population and a rise in lifestyle-related diseases will likely drive demand for gastrointestinal treatments further. As healthcare technology evolves and the government continues to support healthcare initiatives, the landscape for gastrointestinal health will transform, enabling a more proactive approach to treatment and management.
Recent developments in the Vietnam gastrointestinal drugs market indicate a strategic shift towards more patient-centered care. Healthcare providers are increasingly adopting technology-driven solutions that facilitate remote consultations, enhancing access to specialized care. Additionally, there is a growing emphasis on localized drug production to ensure the availability of essential medications while mitigating supply chain disruptions experienced during the pandemic.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Vietnam Gastrointestinal Drugs Market Overview |
3.1 Vietnam Country Macro Economic Indicators |
3.2 Vietnam Gastrointestinal Drugs Market Revenues & Volume, 2022 & 2032F |
3.3 Vietnam Gastrointestinal Drugs Market - Industry Life Cycle |
3.4 Vietnam Gastrointestinal Drugs Market - Porter's Five Forces |
3.5 Vietnam Gastrointestinal Drugs Market Revenues & Volume Share, By Drug Category, 2022 & 2032F |
3.6 Vietnam Gastrointestinal Drugs Market Revenues & Volume Share, By Route of Administration, 2022 & 2032F |
3.7 Vietnam Gastrointestinal Drugs Market Revenues & Volume Share, By Distribution Channel, 2022 & 2032F |
3.8 Vietnam Gastrointestinal Drugs Market Revenues & Volume Share, By Disease Types, 2022 & 2032F |
4 Vietnam Gastrointestinal Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Vietnam Gastrointestinal Drugs Market Trends |
6 Vietnam Gastrointestinal Drugs Market, By Types |
6.1 Vietnam Gastrointestinal Drugs Market, By Drug Category |
6.1.1 Overview and Analysis |
6.1.2 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Drug Category, 2022-2032F |
6.1.3 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Antiemetic, 2022-2032F |
6.1.4 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Acid Neutralizers, 2022-2032F |
6.1.5 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Anti-inflammatory, 2022-2032F |
6.1.6 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Laxatives & Antidiarrheal, 2022-2032F |
6.1.7 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Others, 2022-2032F |
6.2 Vietnam Gastrointestinal Drugs Market, By Route of Administration |
6.2.1 Overview and Analysis |
6.2.2 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Oral, 2022-2032F |
6.2.3 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Parenteral, 2022-2032F |
6.2.4 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Rectal, 2022-2032F |
6.3 Vietnam Gastrointestinal Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Retail Pharmacies, 2022-2032F |
6.3.3 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Online Pharmacies, 2022-2032F |
6.3.4 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Hospital Pharmacies, 2022-2032F |
6.4 Vietnam Gastrointestinal Drugs Market, By Disease Types |
6.4.1 Overview and Analysis |
6.4.2 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Inflammatory Bowel Diseases, 2022-2032F |
6.4.3 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Gastroesophageal Reflux Diseases, 2022-2032F |
6.4.4 Vietnam Gastrointestinal Drugs Market Revenues & Volume, By Others, 2022-2032F |
7 Vietnam Gastrointestinal Drugs Market Import-Export Trade Statistics |
7.1 Vietnam Gastrointestinal Drugs Market Export to Major Countries |
7.2 Vietnam Gastrointestinal Drugs Market Imports from Major Countries |
8 Vietnam Gastrointestinal Drugs Market Key Performance Indicators |
9 Vietnam Gastrointestinal Drugs Market - Opportunity Assessment |
9.1 Vietnam Gastrointestinal Drugs Market Opportunity Assessment, By Drug Category, 2022 & 2032F |
9.2 Vietnam Gastrointestinal Drugs Market Opportunity Assessment, By Route of Administration, 2022 & 2032F |
9.3 Vietnam Gastrointestinal Drugs Market Opportunity Assessment, By Distribution Channel, 2022 & 2032F |
9.4 Vietnam Gastrointestinal Drugs Market Opportunity Assessment, By Disease Types, 2022 & 2032F |
10 Vietnam Gastrointestinal Drugs Market - Competitive Landscape |
10.1 Vietnam Gastrointestinal Drugs Market Revenue Share, By Companies, 2025 |
10.2 Vietnam Gastrointestinal Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here